View PubMed Publications

Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.

Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.

Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.

Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.

Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.

Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.

Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.

View PubMed Publications

Absalon MJ, Smith FO. Treatment strategies for pediatric acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jan;10(1):57-79.

Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F. Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer. 2008 Jun;50(6):1147-53.

Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005 Oct 7;123(1):49-63.

Absalon MJ, Harding CO, Fain DR, Li L, Mack KJ. Leigh syndrome in an infant due to mitochondrial DNA depletion. Pediatr Neurology. 2001; 24:60-63.

View PubMed Publications

Buechele C, Breese EH, Schneidawind D, Lin CH, Jeong J, Duque-Afonso J, Wong SH, Smith KS, Negrin RS, Porteus M, Cleary ML. MLL leukemia induction by genome engineering of human CD34+ hematopoietic cells. Blood. 2015;126(14):1683-1694.

Breese EH, Buechele C, Dawson C, Cleary ML, Porteus M. Use of genome engineering to create patient specific MLL translocations in primary human hematopoietic stem and progenitor cells. PLOS ONE. 2015;10(9):e0136644.

Zhao W, Breese EH, Bowers A, Hoggatt J, Pelus LM, Broxmeyer HE, Goebl MG, Harrington MA. SIMPL enhancement of tumor necrosis factor-alpha dependent p65-MED1 complex formation is required for mammalian hematopoietic stem and progenitor cell function. PLoS ONE. 2013;8(4):e61123.

Breese EH, Dalmau J, Lennon VA, Apiwattanakul M, Sokol DK. Anti-N-methyl-D-aspartate receptor encephalitis: Early treatment beneficial. Pediatric Neurology. 2010;42(3):213-214.

Breese EH, Uversky VN, Georgiadis MM, Harrington MA. The disordered amino-terminus of SIMPL interacts with members of the 70 kDa heat shock protein family. DNA and Cell Biology. 2006;25(12):704-714.

Kwon H-J, Breese EH, Vig-Varga E, Luo Y, Lee Y, Goebl MG, Harrington MA. Tumor necrosis factor alpha induction of NF-κB requires the novel coactivator SIMPL. Molecular and Cellular Biology. 2004;24(21):9317-9326.

View PubMed Publications

Burns K, Broudreau C, Panepinto J. Attitudes Regarding Fertility in Adolescent Females Diagnosed with Cancer. J Pediatr Hematol Oncol. 2006 Jun;28(6): 350-354.

Burns K and Camitta B. Pyrite or True Gold? Journal of Pediatric Hematology/Oncology. 2005 May;27(5): 244.

View PubMed Publications

Hummel, TR, Chow, LML, Fouladi, M, and Franz, D. Pharmacotherapeutic management of pediatric astrocytomas: current and upcoming strategies. Pediatric Drugs 2013; 15:29-42. 

Joshi, K, Banasavadi-Siddegowda, Y, Mo, X, Kim, SH, Mao, P, Kig, C, Nardini, D, Sobol, RW, Chow, LML, Kornblum, HI, Waclaw, R, Beullens, M, and Nakano, I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013; 31:1051-1063. 

Zhong, Y, Wan, Y-W, Pang, K, Chow, LML, and Liu, Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 2013; 14:89. 

Rafalski, VA, Ho, PP, Brett, JO, Ucar, D, Dugas, JC, Pollina, EA, Chow, LML, Ibrahim, A, Baker, SJ, Barres, BA, Steinman, L, and Brunet, A. Expansion of oligodendrocyte progenitor cells upon SIRT1 inactivation in the adult brain. Nature Cell Biol. 2013; 15:614-624. 

Wojton, J, Chu, Z, Mathsyaraja, H, Meisen, WH, Denton, N, Kwon, C-H, Chow, LML, Palascak, M, Franco, R, Bourdeau, T, Thornton, S, Ostrowski, MC,  Kaur, B, and Qi, X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013; 21:1517-1525. 

Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53 and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19:305-316.

Lavado A, Lagutin O, Chow LML, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8:e1000460.

Cicero SA, Johnson D, Reyntjens S, Frase S, Connell S, Chow LML, Baker SJ, Sorrentino BP, Dyer MA. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A. 2009 Apr;106(16):6685-90.

Weber T, Corbett MK, Chow LML, Valentine MB, Baker SJ, Zuo J. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc Natl Acad Sci U S A. 2008;105(2):781-5.

Chow LML, Zhang J, Baker SJ. Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 2008;17(5):919-28. 

View PubMed Publications

Xiaona Liu, Rishi Raj Chhipa and Biplab Dasgupta*. The Selective AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Mol Cancer Ther. *Corresponding author. 2014 Mar:13(3):596-605

Xiaona Liu, Rishi Raj Chhipa, Shabnam Pooya, Matthew Wortman, Sara Yachishin, Ashish Kumar, Lionel Chow, Xuan Zhou, Ying Sun, Brian Quinn, Christopher McPherson, Ronald Warnick, Adi Kendler, Sailendra Giri, Jeroen Poels, Koennard Nogra, Benoit Viollet, Gregory A. Grabowski and Biplab Dasgupta*. Novel mechanisms of mTOR and cdc25c regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sc U S A. *Corresponding author. 2014 Jan 28;111(4):E435-44.

Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B*. Direct inhibition of Retinoblastoma phosphorylation by Nimbolide causes cell cycle arrest and suppresses glioblastoma growth. Clin Cancer Research. 2014 Jan 1:20(1):199-212.

Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, Lindquist D, Milbrandt J. The AMPK beta2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012; 32: 2837-48. Cover article. *Corresponding author.

Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009 Feb;16(2):256-70.

Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007 Apr;24;104(17):7217-22.

Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007 Oct 11;1(4):443-57.

Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005 Jun 8;25(23):5584-94.

Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005 Apr 1;65(7):2755-60.

Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005 Jan 1;65(1):236-45.

View PubMed Publications

 Hummel TR, Salloum R, Drissi R, Kumar S, Sobo M, Goldman S, Pai A, Leach J, Lane A, Pruitt D, Sutton M, Chow LM, Grimme L, Doughman R, Backus L, Miles L, Stevenson C, Fouladi M, DeWire M. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.J Neurooncol. 2016 Mar;127(1):53-61.

Hoffman LM, DeWire M, Ryall S, Buczkowicz P, Leach J, Miles L, Ramani A, Brudno M, Kumar SS, Drissi R, Dexheimer P, Salloum R, Chow L, Hummel T, Stevenson C, Lu QR, Jones B, Witte D, Aronow B, Hawkins CE, Fouladi M. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun. 2016 Jan 4;4(1):1.

Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M. New brain tumour entities emerge from molecular classification of CNS-PNETs. Cell. 2016 Feb 25;164(5):1060-72.

Margol A, Robison N, Gnanachandran J, Hung LT, Kennedy R, Vali M, Muthugounder S, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S. Tumor Associated Macrophages in SHH Subgroup of Medulloblastomas. Clin Cancer Res. 2014 Oct 24.

Dorris K, Sobo M, Onar-Thomas A, Panditharatna E, Stevenson CB, Gardner SL, DeWire MD, Pierson CR, Rempel SA, Olshefski R, Goldman S, Miles L, Fouladi M, Drissi R*. Prognostic Significance of Telomere Maintenance Mechanisms in Pediatric High-Grade Gliomas. Journal of Neuro-Oncology. 2014 Jan 30. (*senior author)

Thompson PA, Drissi R*, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Weigel BJ, Blaney SM. A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Study (ADVL1112). Clin Cancer Res. 2013 Oct 4. (*biology chair)

Sturm D, Witt H, Hovestadt V, Quang DK, Jones DTW, Konermann C, Pfaff E, Sill M, Bender S, Kool M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Rizhova M, Tönjes M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald M, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Milde T, Witt O, Lindroth A, Schwartzentruber J, Faury D, Zakrzewska M, Zakrzewski K, Liberski PP, Zapatka M, Hauser P, Garami M, Klekner A, Bognar L, van Sluis P, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.

Drissi R*, Bockhold CA, Wu J, Dome JS*. Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prev Res. 2011;4(12):1973-1981. (*joint senior author)

Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Shwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambroock PJ, Andreassen PR, Wiesmüller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011;39(17):7465-7476. 

Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004 Sep 15;22(18):3790-7.

View PubMed Publications

Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones D, Capper D, Still M, Boughhalter I, Northcott P, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen S, Balasubramanian G, Worst B, Pajtler K, Brabetz S, Johann P, Sahm F, Reimand J, Mackay A, Carvalho D, Remke M, Phillips J, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Lastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lotsch D, Berger W, Slave I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley B, Schiederjan M, Santi M, Buccoliero A, Dahiya S, Kramm C, Von Hoff K, Rutkowski S, Herold-Mende C, Fruhwald M, Milde T, Hasselblatt M, Wesseling P, Rossler J, Schueller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Scheppenheim R, Zitterbart K, Collins V.P, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, Van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester L, Koster J, Versteeg R, Volckmann R, Van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore A, Taylor M, Jones C, Jabado N, Karajannis M, Eils R, Schlesner M, Lichter P, Vol Deimling A, Pfister S, Ellison D, Korshunov A, Kool M. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016 Feb 25;164(5):1060-72.

Hoffman LM, DeWire M, Ryall S, Buczkowicz P, Leach J, Miles L, Ramani A, Brudno M, Kumar SS, Drissi R, Dexheimer P, Salloum R, Chow L, Hummel T, Stevenson C, Lu QR, Jones B, Witte D, Aronow B, Hawkins CE, Fouladi M. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun. 2016 Jan 4;4(1):1.

Hummel TR, Salloum R, Drissi R, Kumar S, Sobo M, Goldman S, Pai A, Leach J, Lane A, Pruitt D, Sutton M, Chow LM, Grimme L, Doughman R, Backus L, Miles L, Stevenson C, Fouladi M, DeWire M. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J Neurooncol. 2016 Mar;127(1):53-61.

Poussaint TY, Vajapeyam S, Ricci KI, Panigrahy A, Kocak M, Kun LE, Boyett JM, Pollack IF, Fouladi M. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2015 Oct 20.

Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C, Leasure J, Smith PD, Kurmasheva RT, Mo X, Fouladi M, Houghton PJ. Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatr Blood Cancer. 2015 Oct;62(10):1768-74.

Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep;31(9):1433-45.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20;33(24):2646-54.

Davis J, Kreppel AJ, Brady RC, Jones B, Stevenson CB, Fouladi M, Hummel TR. Nocardia farcinica Meningitis Masquerading as Central Nervous System Metastasis in a Child With Cerebellar Pilocytic Astrocytoma. J Pediatr Hematol Oncol. 2015 Aug;37(6):482-5.

Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9.

Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015 Jul;21(7):827.

View PubMed Publications

Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.

Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.

Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.

Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.

Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.

Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.

Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.

Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.

Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.

Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.

View PubMed Publications

Hammill AM, Wentzel MS, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011 Dec 1; 57(6):1018-1024.

Drolet BA, Trenor CC, Brandao L, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus –derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013 Jul; 163(1):285-91.

Jeng MR, Fuh B, Blatt J, Gupta A, Merrow AC, Hammill A, Adams D. Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab. Pediatr Blood Cancer. 2014 Nov; 61(11): 2115-7.

Adams D, Hammill A. Other vascular tumors. Sem Ped Surg. 2014 Aug; 23(4) 173-7.

Burkes SA, Adams DM, Hammill AM, Chute C, Eaton KP, Welge JA, Wickett RR, Visscher MO. Skin Imaging Modalities Quantify Progression and Stage of Infantile Hemangiomas. Br J Dermatol. 2015 Sep; 173(3):838-41.

Adams DM, Hammill AM, Mobberley-Schuman PS, Trenor CC. Comment on: Steroid-resistant kaposiform hemangioendothelioma: A retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer. 2015 Nov; 62(11):2056.

View PubMed Publications

Gass D, Dewire M, Chow L, Rose SR, Lawson S, Stevenson C, Pai AL, Jones B, Sutton M, Lane A, Pruitt D, Fouladi M, Hummel TR. Pediatric tectal plate gliomas: a review of clinical outcomes, endocrinopathies, and neuropsychological sequelae. J Neurooncol. 2015 Jan 13.

Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D'Agostino McGowan L, Liu GT. Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol. 2014 May;75(5):799-800.

Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep;60(9):1452-7.

Hummel TR, Chow LM, Fouladi M, Franz D. Pharmacotherapeutic Management of Pediatric Gliomas: Current and Upcoming Strategies. Pediatric Drugs. 2012.

Hummel TR, Miles L, Mangano FT, Jones BV, Geller JI. Clinical heterogeneity of desmoplastic infantile ganglioglioma: a case series and literature review. J Pediatr Hematol Oncol. 2012 Aug;34(6):e232-6.

Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu G. Visual outcomes in children with neurofibromatosis type 1–associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun;14(6):790-7.

Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7.

Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-Related Plexiform Neurofibroma to High Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90.

Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner V, Wallace M, Lázaro C, Page G, Worley P, Aronow B, Schorry E, Ratner N. Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin. Clin Cancer Res. 2010 Oct 15;16(20):5048-57.

Hummel T, Hord J. Favorable Response to Soft Tissue Sarcoma Therapy in Adolescent with Embryonal Renal Sarcoma. Pediatr Blood Cancer. 2004 Jul;
43(1):70-2.

View PubMed Publications

View PubMed Publications

Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013 Mar 21;121(12):e90-7.

Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC. The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood. 2012;120(4):709-19.

Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JC. Inhibition of Rac GTPase signaling and downstream pro-survival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood. 2011 118(19):5235-45.

Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA.  Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2011 56(5): 840-2.

Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF, and IL-3. Leukemia. 2010; 24(10):1785-8.

View PubMed Publications

Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34.

Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.

Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44.

Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65.

Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.

Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.

Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79.

Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.

Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6.

Book Chapters

Spector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.

View PubMed Publications

Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010 Nov;9(11):2970-81.

O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 May;54(5):694-702.

O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010 Mar 1;28(7):1232-9.   

Jeng MR, O’Brien M, Wong W, Zoland J, Lea J, Tang N, Glader B.  Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia. Haemophilia. 2009 Nov 15(6):1272-80.

Donaldson SS, O'Brien MM. Understanding the risk of second malignant tumors in children with Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):4-5.

O’Brien MM, Lee-Kim Y, George T, McClain K, Twist C, Jeng M.   Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis: case series and review of the literature. Pediatr Blood Cancer. 2008 Feb 50(2):381-3

O’Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV.  Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children’s Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 26(3):414-420.

View PubMed Publications

Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with Melanotic Differentiation: Case Report and Review of the Literature. J Neurooncol. 2011 Jul;103(3):759-64.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 Polymorphism Increases Susceptibility to Childhood Acute Myeloid Leukemia. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

View PubMed Publications

Kaylani SZ, Xu J, Srivastava RK, Kopelovich L, Pressey JG, Athar M. Rapamycin Targeting mTOR and Hedgehog Signaling Pathways Blocks Human Rhabdomyosarcoma Growth in Xenograft Murine Model. Biochem Biophys Res Commun. 2013 Jun 14;435(4):557-61.

Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WPD, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Bodour S, Prat J, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RBS, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations of SMARCA4. Nat Genetics. 2014 May;46(5):427-9.

Pressey JG, Kelly DR, Hawthorne HT. Successful treatment of preadolescents with small cell carcinoma of the ovary hypercalcemic type. J Pediatr Hematol Oncol. 2013 Oct;35(7):566-9.

Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, Friedman GK. CD133 Marks a Myogenically Primitive Subpopulation in Rhabdomyosarcoma Cell Lines that are Relatively Chemoresistant but Sensitive to Mutant HSV. Pediatr Blood Cancer. 2013 Jan; 60(1):45-52.

Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG. Hedgehog Pathway Activity in Pediatric Embryonal Rhabdomyosarcoma and Undifferentiated Sarcoma: A Report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8.

Pressey JG, Pressey CS, Kelly DR, Robinson G, Herron R, Wilson L, Kim H. 2D-Difference Gel Electrophoretic Proteomic Analysis of a Cell Culture Model of Alveolar Rhabdomyosarcoma. J Proteome Res. 2011 Feb 4;10(2):624-36.

Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets C, Kopelovich L, Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010 Aug 15;70(16):6566-76.

Friedman GF, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies. Mol Ther. 2009 Jul;17(7):1125-35.

Siegel HJ, Pressey JG. Current Concepts in the Surgical and Medical Management of Osteosarcoma. Expert Rev Anticancer Ther. 2008 Aug;8(8):1257-69.

Womer RB, Pressey JG. Rhabdomyosarcoma and soft tissue sarcoma in childhood. Curr Opin Oncol. 2000 Jul ;12: 337-44.

View PubMed Publications

Pease NA, Wise-Draper TM, Privette Vinnedge LM. Dissecting the potential interplay of DEK functions in inflammation and cancer. Journal of Oncology. 2015.

Privette Vinnedge LM, Benight N, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas J, Waltz SE, Wells SI. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor positive breast cancers. Oncogene. 2015 Apr 30;34(18):2325-36.

Privette Vinnedge LM, Kappes F, Nassar N, Wells SI. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle. 2013 Jan 1;12(1):51-66.

Privette Vinnedge LM, Wikenheiser-Brokamp KA, Ho S-M, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling. PLoS One. 2012;7(10):e46985.

Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates beta catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011 Jun 16;30(24):2741-52.

Gonzalez ME, Makarova O, Peterson EA, Privette LM, Petty EM. Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal Kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cellular Signaling. 2009 Apr;21(4):477-487.

Privette LM, Petty EM. CHFR: a novel mitotic checkpoint protein and regulator of tumorigenesis. Translational Oncology. 2008 Jul;1(2):57-64.

Privette LM, Weier JF, Nguyen HN, Yu X, Petty EM. Loss of CHFR expression in mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia. 2008 Jul;10(7):643-652.

Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Research. 2007 Sep 15;67(18):8554-64.

Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint gene, CHFR, in breast cancers: Implications for tumor suppression. Cancer Research. 2007 Jul 1;67(13):6064-74.

View PubMed Publications

Auble BA, Makoroff K, Bollepalli S, Weis T, Colliers T, Khoury J, Rose SR. Hypopituitarism in pediatric survivors of inflicted traumatic brain injury. J Neurotrauma. 2014 Feb 15;31(4):321-6.

Myers KC, Rose SR, Rutter MM, Mehta PA, Cole T, Harris RE. Endocrine evaluation of children with and without Shwachman-Bodian-Diamond syndrome gene mutations and Shwachman-Diamond syndrome. J Pediatr. 2013 Jun;162(6):1235-40.

Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012 Dec;22(12):1046-56.

Rose SR, Myers K, Rutter MM, Mueller R, Khuory JC, Mehta PA, Harris RE, Davies SM. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012 Oct;59(4):690-6. 

Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011 Dec 20;29(36):4776-80.

Kaulfers AM, Backeljauw PF, Reifschneider K, Blum S, Michaud L, Weiss M, Rose SR. Endocrine dysfunction following traumatic brain injury in children. J Pediatr.  2010 Dec;157(6): 894-9.

Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr. 2010 Oct;157(4):662-7.

Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, Akinbi HT. The effects of gestational age and birth weight on false-positive newborn screening rates. Pediatrics. 2010 Nov;126(5):910-6.

Kazlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, Choi CH, Courtney CH, Gonc EN, Maghnie M, Oelkers W, Rose SR, Soule SG, Tordjman K, Consortium for evaluation of corticotropin test in hypothalamic-pituitary insufficiency. Corticotropin tests for hypothalamic-pituitary adrenal insufficiency: A metaanalysis. J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53.

Rose SR. Pharmacologic and physiologic regulators of the nocturnal TSH surge; A clinical research center study. Recent Advances and Research Updates. ISSN 0972-4699, 2007; 8:219-29.

View PubMed Publications

Fells JI, Lee SC, Fujiwara Y, Norman DD, Lim KG, Tsukahara R, Liu J, Patil R, Miller DD, Kirby RJ, Nelson S, Seibel W, Papoian R, Parrill AL, Baker DL, Bittman R, Tigyi G.  Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.  Mol Pharmacol. 2013 Sep;84(3):415-24.

Cash JN, Angerman EB, Kirby RJ, Merck L, Seibel WL, Wortman MD, Papoian R, Nelson S, Thompson TB.  Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A.  J Biomol Screen. 2013 Aug;18(7):837-44.

Panmanee W, Taylor D, Shea CJ, Tang H, Nelson S, Seibel W, Papoian R, Kramer R, Hassett DJ, Lamkin TJ.  High-throughput screening for small-molecule inhibitors of Staphylococcus epidermidis RP62a biofilms.  J Biomol Screen. 2013 Aug;18(7):820-9.

Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M, Zheng Y. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60.

Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, Seibel W, Wortman M, Zheng Y.  Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol. 2012 Jun 22;19(6):699-710.

Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S, Dong Z. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.  Mol Pharmacol. 2012 Jun;81(6):811-9.

Bosco EE, Kumar S, Marchioni F, Biesiada J, Kordos M, Szczur K, Meller J, Seibel W, Mizrahi A, Pick E, Filippi MD, Zheng Y.  Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation.  Chem Biol. 2012 Feb 24;19(2):228-42.

Barger JF, Gallo CA, Torni KA, Merk L, Seibel WL, Nelson S, Plas DR. Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to rapamycin. Cancer Biol Ther. 2010 Dec 15;10(12):1256-61.

Rathore R, Pribil P, Corr JJ, Seibel WL, Evdokimov A, Greis KD. Multiplex enzyme assays and inhibitor screening by mass spectrometry.  J Biomol Screen.  2010 Sep;15(8):1001-7.

Rathore R, Corr JJ, Lebre DT, Seibel WL, Greis KD. Extending matrix-assisted laser desorption/ionization triple quadrupole mass spectrometry enzyme screening assays to targets with small molecule substrates. Rapid Commun Mass Spectrom.  2009 Oct 30;23(20):3293-300.

View PubMed Publications

Trout A, Sharp S, Turpin B, Zhang B, Gelfand M. Optimizing the interval between G-CSF therapy and F18 FDG-PET imaging in children and young adult patients receiving chemotherapy for sarcoma. Pediatric Radiology. 2015 Jul;45(7):1001-6.

Andersson C, Kvist PH, McElhinney K, Baylis R, Gram LK, Pelzer H, Lauritzen B, Holm TL, Hogan S, Wu D, Turpin B, Miller W, Palumbo JS. Factor XIII Transglutaminase Supports the Resolution of Mucosal Damage in Experimental Colitis. PLoS One. 2015 Jun 22;10(6):e0128113.

Turpin*, Whitney Miller*, Leah Rosenfeldt, Keith Kombrinck, Matthew J. Flick, Kris A. Steinbrecher, Eleana Harmel-Laws, Eric S. Mullins, Maureen Shaw, David P. Witte, Alexey Revenko, Brett Monia, Joseph S. Palumbo. (* signifies equal contributors). Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 2014 Jun 1;74(11):3020-30.

Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot Study of Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) Combined with Bevacizumab in Pediatric Patients with Recurrent Solid Tumors or Brain Tumors. Pediatr Blood Cancer. 2013 Apr 29.

Turpin BK, Morris VR, Lemen L, Weiss BD, Gelfand MJ. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy. Health Phys. 2013 Feb; 104(2 Suppl 1):S43-6.

Trehan I, Turpin BK. Neonatal respiratory distress due to bilateral dacrocystoceles. J Pediatr. 2008 Sep;153(3):438.

Turpin B, Tobias JD. Perioperative management of a child with short-chain acyl-CoA dehydrogenase deficiency. Paediatr Anaesth. 2005 Sep;15(9):771-7.

Cogar BD, Groshong TD, Turpin BK, Guajardo JR. Chylothorax in Henoch-Schonlein purpura: a case report and review of the literature. Pediatr Pulmonol. 2005 Jun;39(6):563-7.

View PubMed Publications

Sharp SE, Trout AT, Weiss B, Gelfand M. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics. 2016 Jan-Feb;36(1):258-78.

Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016 Feb;137(2):1-10.

Dandoy CE, Hariharan S, Weiss B, Demmel K, Timm N, Chiarenzelli J, Dewald MK, Kennebeck S, Langworthy S, Pomales J, Rineair S, Sandfoss E, Volz-Noe P, Nagarajan R, Alessandrini E. Sustained reductions in time to antibiotic delivery in febrile immunocompromised children: results of a quality improvement collaborative. BMJ Qual Saf. 2016 Feb;25(2):100-9.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen EC, Giacomini KM, Weiss B, Cohn SL, Granger M, Yanik GA, Hawkins R, Courtier J, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei DD, Villablanca JG, Marachelian A, Matthay KK. Phase 1 Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15;21(12):2715-21.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015 Apr;21(4):673-81.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr;17(4):596-603.

Salloum R, Garrison A, von Allmen D, Sheridan R, Towbin AJ, Adams D, Weiss B. Relapsed perinatal neuroblastoma after expectant observation. Pediatr Blood Cancer. 2015 Jan;62(1):160-2.

Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit. 2015 Jun;37(3):395-9.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC. Update from the 2013 international neurofibromatosis conference. Am J Med Genet A. 2014 Dec;164A(12):2969-78.

Dandoy C, Davies S, Flesch L, Hayward M, Koons C, Coleman K, Jacobs J, McKenna L, Olomajeye A, Olson C, Powers J, Shoemaker K, Jodele S, Alessandrini E, Weiss B. A Team-Based Approach to Reducing Cardiac Monitor Alarms. Pediatrics. 2014 Dec;134(6)e1686-94.

View PubMed Publications

Bahassi M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ. Rixe O.  A patient-derived somatic mutation in the epidural growth factor ligand-binding domain confers increased sensitivity to cetuximab in heck and neck cancer. European J Cancer. 2013 Jul:49(10):2345-55.

Privette Vinnedge LM, Ho SM. Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLoS One. 2012;7(10):e46985.

Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Butsch Kovacic M, Wikenheiser-Brokamp KA, Wells SI. The Fanconi anemia pathway limits human papillomavirus replication. J Virol. 2012 Aug;86(15);8131-8.

Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI, Future directions  and treatment strategies for head and neck squamous cell carcinomas. Transl Res. 2012 Sep;160(3):167-77.

Morrison MA, Morreale RJ, Akunuru S, Kofron M, Zheng Y, Wells SI. Targeting the human papillomavirus E6 and E7 oncogenes through  expression of the BPV1 E2 protein stimulates cellular motility. J Virol. 2011 Oct;85(20):10487-98.

Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Mehta PA.  Impaired immune function in children with Fanconi anaemia. Br J Haematol. 2011 Jul;154(2):234-40.

Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmuller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucl Acids Res. 2011 Sep 1;39(17):7465-76.

Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011 Jun 16;30:2741-52.

Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Toile K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011 Feb 3;470(733):105-9.

Meyer SE, Peace BE, Bahassi el M, Kavanaugh GM, Wagh PK, Robbins SB, Yin M,Wells SI, Zinser GM, Stambrook PJ, Waltz SE. Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice. Cancer Lett. 2010 Oct 28;296(2):186-93.